Evidence map›Paper›PMID 37760631›Full record

ArticleCancers2023

Polo-like Kinase 4: A Multifaceted Marker Linking Tumor Aggressiveness and Unfavorable Prognosis, and Insights into Therapeutic Strategies.

Youngtaek Kim, Joon Yeon Hwang, Dong Kwon Kim, Kwangmin Na, Seul Lee, Sujeong Baek, Seong-San Kang, Seung Min Yang, Mi Hyun Kim, Heekyung Han and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Youngtaek KimDepartment of Research Support, Yonsei Biomedical Research Institute, Yonsei University College of Medicine, Seoul 03186, Republic of Korea.ORCID 0009-0001-3045-9678
Joon Yeon HwangDepartment of Research Support, Yonsei Biomedical Research Institute, Yonsei University College of Medicine, Seoul 03186, Republic of Korea.
Dong Kwon KimSeverance Biomedical Science Institutse, Yonsei University College of Medicine, Seoul 03186, Republic of Korea.ORCID 0000-0002-1407-2369
Kwangmin NaDepartment of Research Support, Yonsei Biomedical Research Institute, Yonsei University College of Medicine, Seoul 03186, Republic of Korea.
Seul LeeSeverance Biomedical Science Institutse, Yonsei University College of Medicine, Seoul 03186, Republic of Korea.
Sujeong BaekDepartment of Research Support, Yonsei Biomedical Research Institute, Yonsei University College of Medicine, Seoul 03186, Republic of Korea.
Seong-San KangJEUK Institute for Cancer Research, JEUK Co., Ltd., Gumi 39418, Republic of Korea.
Seung Min YangDepartment of Research Support, Yonsei Biomedical Research Institute, Yonsei University College of Medicine, Seoul 03186, Republic of Korea.
Mi Hyun KimDepartment of Research Support, Yonsei Biomedical Research Institute, Yonsei University College of Medicine, Seoul 03186, Republic of Korea.
Heekyung HanDepartment of Research Support, Yonsei Biomedical Research Institute, Yonsei University College of Medicine, Seoul 03186, Republic of Korea.
Chai Young LeeDepartment of Research Support, Yonsei Biomedical Research Institute, Yonsei University College of Medicine, Seoul 03186, Republic of Korea.
Yu Jin HanDepartment of Research Support, Yonsei Biomedical Research Institute, Yonsei University College of Medicine, Seoul 03186, Republic of Korea.
Min Hee HongDivision of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul 03186, Republic of Korea.ORCID 0000-0003-3490-2195
Jii Bum LeeDivision of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul 03186, Republic of Korea.ORCID 0000-0001-5608-3157
Sun Min LimDivision of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul 03186, Republic of Korea.
Byoung Chul ChoDivision of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul 03186, Republic of Korea.
Youngjoon ParkDepartment of Research Support, Yonsei Biomedical Research Institute, Yonsei University College of Medicine, Seoul 03186, Republic of Korea.
Kyoung-Ho PyoSeverance Biomedical Science Institutse, Yonsei University College of Medicine, Seoul 03186, Republic of Korea.ORCID 0000-0001-5428-0288
Yonsei University · KRJeuk (South Korea) · KR

Funding

National Research Foundation of Korea 2022M3E5F3081138
6 · The paper itself

Abstract

(1) Background: This study investigated whether polo-like kinase 4 (PLK4) is a suitable therapeutic target or biomarker for lung adenocarcinoma (LUAD). (2) Methods: We acquired LUAD data from The Cancer Genome Atlas (TCGA) database through the UCSC Xena data portal. Gene expression, clinical, survival, and mutation data from multiple samples were analyzed. Gene enrichment analysis, unsupervised clustering of

Indexed as

biomarkersdrug resistancelung adenocarcinomaPLK4TP53

Identifiers

PMID37760631
PMCPMC10526937
OpenAlexW4386912953

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.